Research Site

Morristown, New Jersey 08057

1 studies enrolling now · 30 studies all time

What they study most

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck, Anemia, Bladder Cancer, Breast Cancer, Carcinoma, Cardiovascular Disease, Cerebral Stroke, Cerebrovascular Stroke, Chronic Lymphocytic Leukemia, Congestive Heart Failure, Crohn's Disease, Diabetes Mellitus, Type 2

Studies at this site

• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL — Running, not enrolling
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
• Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma — Running, not enrolling
• A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection — Running, not enrolling
• A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL — Running, not enrolling
• Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck — Completed
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer — Running, not enrolling
• Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma — Completed
• Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim — Completed
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
• Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer — Completed
• Safety Study of Entocort for Children With Crohn's Disease — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma — Status unconfirmed
• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma — Completed
• An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants — Completed
• Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma — NO_LONGER_AVAILABLE
• Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) — Stopped early
• JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events — Stopped early
• A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer — Completed
• A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis. — Stopped early
• Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed
• Iressa Expanded Access Program (EAP) — Completed
• CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy — Completed
• A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer — Completed
• Esomeprazole for Treatment of GERD in Pediatric Patients — Completed
• Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed